TEST:

VENTANA PD-L1 (SP263) Assay

P3, N=68, Active, not recruiting, Hoffmann-La Roche | Trial primary completion date: Dec 2026 --> Jun 2030

PD-L1 expression is independently associated with worse survival outcomes in patients with early-stage NSCLC treated with SBRT, indicating its potential as a prognostic biomarker for risk stratification.

AI-assisted assessment demonstrates high concordance with the expert pathologist, particularly in binary classification. However, due to discrepancies in the intermediate range, the algorithm is currently best positioned as a supportive tool for verifying borderline cases.

By evaluating PD-L1 expression in premalignant lesions and histologically negative margins, this study aims to identify molecular predictors of OSCC progression and survival. The findings may help establish PD-L1 as a prognostic biomarker and support its integration into precision oncology and immunotherapy strategies.

In this real-world cohort, adjuvant atezolizumab demonstrated favorable tolerability and clinically meaningful DFS across PD-L1 expression subgroups, including patients with PD-L1 1-49%. These findings are descriptive in nature and should be interpreted with caution, nevertheless, they provide real-world evidence supporting the potential clinical utility of adjuvant atezolizumab in appropriately selected patients with resected stage II-III NSCLC.

Our results suggest that cPD-L1 expression in most sUC occurs secondary to IL6-JAK-STAT3 and interferon α/γ signaling. This provides a biologic rationale for evaluating response to immunotherapy in this patient population.

P1, N=210, Active, not recruiting, iOnctura | Trial completion date: Mar 2025 --> Mar 2027

P1, N=24, Terminated, Imugene Limited | Active, not recruiting --> Terminated; Portfolio prioritization

P3, N=71, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Sep 2033 --> Jun 2030 | Trial primary completion date: Aug 2032 --> Dec 2026

In our patient population we found that the PD-L1 expression in relapse/refractory lymphoma biopsy in comparison to primary diagnosis biopsy remains largely unchanged in HRS cells and in the microenvironment. This stable expression of PD-L1 expression in paired biopsies suggests that PD-L1 inhibitors can be used as second line therapy in all relapsed Classical Hodgkin lymphoma patients without PD-L1 testing.

P2/3, N=246, Recruiting, Pfizer Inc.

P2, N=61, Not yet recruiting, Guangdong Association of Clinical Trials